Alec Stranahan

Ami Fadia

Andrea Newkirk

Andres Maldonado

Tara Bancroft

Joseph Catanzaro

Priyanka Grover

Soumit Roy

Andrea Tan

Anupam Rama

- Day One (DAWN) reported **Q3 2025 net product revenue of $38.5 million**, representing a **15% quarter-over-quarter increase**, and year-to-date net product revenue of **$102.6 million**.  **[0001845337_2233280_1]** **[0001845337_2233280_2]** **[0001845337_2233280_4]** 
- The company **raised its full-year 2025 revenue guidance** to a new range of **$145-$150 million**.  **[0001845337_2233280_1]** **[0001845337_2233280_3]** **[0001845337_2233280_4]** 
- OJEMDA demonstrated strong performance with total prescriptions growing **18%** to **over 1,200** and new patient starts accelerating by almost **20%** quarter over quarter.  **[0001845337_2233280_2]** 
- Operating expenses for Q3 were **$59.6 million**, a **9% decrease** compared to Q2, and the company ended the quarter with **$451.6 million in cash** and no debt.  **[0001845337_2233280_4]** 
- Key pipeline advancements include FIREFLY-2 remaining on track for full enrollment in the first half of 2026, and Tovorafenib being added to the National Comprehensive Cancer Network adult glioma treatment guidelines.  **[0001845337_2233280_1]**

Day One Reports Strong Q3 2025 Results and Raises Full-Year Guidance

- DAWN reported **$38.5 million** in OJEMDA net product revenue for Q3 2025, reflecting a **15%** growth compared to Q2 2025.  **[0001845337_2232887:6]** **[0001845337_2232887:9]**  Year-to-date net product revenue reached **$102.6 million**.  **[0001845337_2232887:6]** **[0001845337_2232887:9]** 
- Total revenue for Q3 2025 was **$39.8 million**, resulting in a net loss of **($19.7 million)** for the quarter.  **[0001845337_2232887:9]** 
- The company maintained a strong financial position with **$451.6 million** in cash, cash equivalents, and short-term investments as of September 30, 2025.  **[0001845337_2232887:6]** **[0001845337_2232887:9]** 
- DAWN raised its 2025 guidance for net product revenue to **$145 million - $150 million**.  **[0001845337_2232887:6]** **[0001845337_2232887:8]** 
- OJEMDA prescriptions (TRx) increased by **18%** to **1,256** in Q3 2025, with new patient starts growing by **19%**.  **[0001845337_2232887:6]** **[0001845337_2232887:7]**

DAWN announces Q3 2025 financial results and raises full-year guidance

- **OJEMDA net product revenue** for the third quarter of 2025 was **$38.5 million**, representing a **15% increase** from the second quarter of 2025, with year-to-date net product revenue reaching **$102.6 million**.  **[1845337_0001193125-25-264608_dawn-ex99_1.htm:0]** **[1845337_0001193125-25-264608_dawn-ex99_1.htm:0]** **[1845337_0001193125-25-264608_dawn-ex99_1.htm:1]** **[1845337_0001193125-25-264608_dawn-ex99_1.htm:1]** **[1845337_0001193125-25-264608_dawn-ex99_2.htm:5]** **[1845337_0001193125-25-264608_dawn-ex99_2.htm:6]** **[1845337_0001193125-25-264608_dawn-ex99_2.htm:7]** **[1845337_0001193125-25-264608_dawn-ex99_3.htm:10]** 
- The company is **raising its OJEMDA full-year 2025 net product revenue guidance** to **$145 to $150 million**.  **[1845337_0001193125-25-264608_dawn-ex99_1.htm:0]** **[1845337_0001193125-25-264608_dawn-ex99_1.htm:0]** **[1845337_0001193125-25-264608_dawn-ex99_2.htm:5]** **[1845337_0001193125-25-264608_dawn-ex99_2.htm:6]** **[1845337_0001193125-25-264608_dawn-ex99_3.htm:6]** 
- Day One Biopharmaceuticals reported a **net loss** of **$19.7 million** for the third quarter of 2025.  **[1845337_0001193125-25-264608_dawn-ex99_1.htm:1]** **[1845337_0001193125-25-264608_dawn-ex99_1.htm:1]** **[1845337_0001193125-25-264608_dawn-ex99_2.htm:7]** **[1845337_0001193125-25-264608_dawn-ex99_3.htm:10]** 
- The company ended the third quarter of 2025 with **$451.6 million** in cash, cash equivalents, and short-term investments as of September 30, 2025.  **[1845337_0001193125-25-264608_dawn-ex99_1.htm:0]** **[1845337_0001193125-25-264608_dawn-ex99_1.htm:0]** **[1845337_0001193125-25-264608_dawn-ex99_1.htm:1]** **[1845337_0001193125-25-264608_dawn-ex99_1.htm:1]** **[1845337_0001193125-25-264608_dawn-ex99_2.htm:5]** **[1845337_0001193125-25-264608_dawn-ex99_2.htm:7]** **[1845337_0001193125-25-264608_dawn-ex99_3.htm:10]** 
- Three-year FIREFLY-1 data is scheduled to be released in an oral presentation at the Society for Neuro-Oncology on **November 23, 2025**.  **[1845337_0001193125-25-264608_dawn-ex99_1.htm:0]** **[1845337_0001193125-25-264608_dawn-ex99_1.htm:0]** **[1845337_0001193125-25-264608_dawn-ex99_1.htm:1]** **[1845337_0001193125-25-264608_dawn-ex99_1.htm:1]** **[1845337_0001193125-25-264608_dawn-ex99_2.htm:5]** **[1845337_0001193125-25-264608_dawn-ex99_3.htm:6]** **[1845337_0001193125-25-264608_dawn-ex99_2.htm:7]**

Day One Biopharmaceuticals Reports Q3 2025 Financial Results and Raises Full-Year Guidance

Day One Biopharmaceuticals (DAWN)